LAPTOP Study: A 24-Month Trial of Verteporfin Versus Ranibizumab for Polypoidal Choroidal Vasculopathy

Oishi, Akio; Miyamoto, Noriko; Mandai, Michiko; Honda, Shigeru; Matsuoka, Toshifumi; Oh, Hideyasu; Kita, Mihori; Nagai, Tomoko; Bessho, Nobuhiro; Uenishi, Mamoru; Kurimoto, Yasuo; Negi, Akira

doi:10.1016/j.ophtha.2013.12.037

Cited by 66 publications

(45 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When comparing the efficacy of anti-VEGF (ranibizumab) monotherapy to PDT monotherapy, one study found superior visual improvement using ranibizumab (30%) compared to PDT(17%). (102) This finding was also noted in a subsequent study. (82) Ranibizumab, bevacizumab, aflibercept, ziv-aflibercept, and conbercept have all been used as therapeutic anti-VEGF agents for PCV and have been shown to reduce exudation and stabilize or improve vision, but have variable effects on polypoidal lesions and choroidal vascular abnormalities.…”

Section: Management Of Pcvsupporting

confidence: 78%

Polypoidal Choroidal Vasculopathy

Kim

Nirwan

Kuriyan

2017

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Purpose of Review The goal of this paper is to review the recent literature of polypoidal choroidal vasculopathy (PCV) and provide an update on the epidemiology, pathophysiology, clinical findings, and management. Recent Findings Although indocyanine-green angiography (ICGA) is still the gold standard for diagnosis of PCV, the use of en face optical coherence tomography (OCT) and OCT angiography are useful tools in the diagnosis of PCV. Studies demonstrate superior treatment outcomes with combination photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) therapy. Summary PCV is a disease most commonly in Asians and African-Americans and presents with an orange-red nodule in the macula or the peripapillary region. While ICGA remains the most accurate method to diagnose PCV, newer non-invasive imaging modalities (eg. OCT-A and en face OCT) can be used to identify PCV lesions. The combination of PDT and anti-VEGF therapy is superior to either monotherapy. Future studies of OCT modalities and other anti-VEGF agents will be important in guiding PCV diagnosis and management, respectively.

show abstract

Section: Management Of Pcvsupporting

confidence: 78%

Polypoidal Choroidal Vasculopathy

Kim

Nirwan

Kuriyan

2017

Curr Ophthalmol Rep

View full text Add to dashboard Cite

show abstract

“…17 Thus, it would be interesting to evaluate the effects of adjunctive therapies in PCVs with multiple polyps in a future study.…”

Section: In This Study We Compared the Responses Of Pcv Pa-mentioning

confidence: 99%

“…15 Moreover, reports of the posttreatment prognosis of PCV patients are inconsistent among clinical studies. [16][17][18][19][20][21] For example, a randomized study (the EVEREST study) compared the efficacy of IVR and photodynamic therapy (PDT) for the treatment of PCV and concluded that the latter was more effective in achieving polyp regression. 16 In contrast, another study (the LAPTOP study) showed that IVR monotherapy was superior to PDT.…”

mentioning

confidence: 99%

“…16 In contrast, another study (the LAPTOP study) showed that IVR monotherapy was superior to PDT. 17 These differences probably occurred because of the lack of detailed classifications for the different variants of PCV that exhibit different responses to treatment. Therefore, classifications that accurately represent the prognosis of each variant are desirable.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps

Suzuki

Nagai

Shinoda

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The efficacy between the two treatment modalities was not statistically different for visits from 6 months to 2 years. The LAPTOP (the comparison of ranibizumab (Lucentis) And Photodynamic Therapy On Polypoidal choroidal vasculopathy) study,9 prospective randomised trial, showed that three monthly injections followed by as-needed injections of ranibizumab could achieve better 24-month visual outcomes than PDT monotherapy. Thus, the treatment strategy for PCV is still debated.…”

mentioning

confidence: 99%